Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Eisai President Naito Awarded Honorary KBE
April 16, 2014
- FY2015 Recruitment Plan: Eisai to Resume Offering Jobs to New Graduates
April 15, 2014
- Novartis Pharma Notified Police about Metal Object Found in Voltaren Product
April 15, 2014
- Hisamitsu Total Sales Up 5.5% but Domestic Ethical Drug Sales Down 1.8%
April 14, 2014
- Patient Enrollment for PI Trial of Anticancer Drug HF10 in US Completed, Takara Bio
April 14, 2014
- RaQualia, Asahi Kasei Pharma Conclude Joint Drug Discovery Research
April 14, 2014
- 10% of Valsartan Franchise Prescriptions Switched to Other ARBs, Azilva, Micamlo Top Lists
April 11, 2014
- Chugai Files NDA for Vemurafenib for Melanoma with BRAF Mutation, Roche Diagnostics Files for Companion Diagnostics
April 11, 2014
- 17 Patients Who Took Xeplion Have Died since November Launch
April 10, 2014
- Kyowa Kirin Completes Biopharmaceutical API Manufacturing Facility, Eying Start of Operations from 2016
April 10, 2014
- Announcement: 7th Annual Marketing Excellence Japan 2014 – Westin Tokyo, May 13 – 14
April 9, 2014
- US Jury Orders Takeda to Pay US$6 Billion in Punitive Damages
April 9, 2014
- GSK Voluntarily Recalls Paxil in Japan, No Reports of Adverse Reactions
April 9, 2014
- ViiV, Shionogi to Copromote Anti-HIV Drug Tivicay at 100 Major Facilities
April 9, 2014
- DSP Subsidiary Sunovion Launches Antiepileptic Drug Aptiom in US
April 9, 2014
- Livalo Lawsuit: Does Use of “PITAVA” by Generic Makers Infringe Kowa Trademark?
April 9, 2014
- Ethical Drug Sales Up 3.0% in February Due to Flu Epidemic: Crecon Report
April 9, 2014
- Bayer Yakuhin Sales Up 16.5% Driven by New Product Growth
April 9, 2014
- Oncolys, BMS End Collaboration for Anti-HIV Drug Development
April 9, 2014
- Santen Licenses Tafluprost Marketing Rights in US to Oak Pharmaceuticals
April 9, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…